Vera Therapeutics, Inc. (VERA) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Brisbane, CA, United States. Der aktuelle CEO ist Marshall W. Fordyce.
VERA hat IPO-Datum 2021-05-14, 152 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $3.17B.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for serious immunological diseases in the United States. The company's lead candidate, atacicept, is a fusion protein administered via subcutaneous injection currently in Phase IIb trials for immunoglobulin A nephropathy. Vera is also advancing MAU868, a monoclonal antibody in Phase 2 development for treating BK viremia infections. Founded in 2016 and headquartered in Brisbane, California, the company was previously known as Trucode Gene Repair, Inc. before rebranding as Vera Therapeutics in April 2020.
